These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36715299)

  • 1. Pharmacokinetics of a proposed tocilizumab biosimilar (MSB11456) versus US-licensed tocilizumab: results of a randomized, double-blind, single-intravenous dose study in healthy adults.
    Tomaszewska-Kiecana M; Ullmann M; Petit-Frere C; Monnet J; Dagres C; Illes A
    Expert Rev Clin Immunol; 2023 Apr; 19(4):439-446. PubMed ID: 36715299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial.
    Schwabe C; Illes A; Ullmann M; Ghori V; Vincent E; Petit-Frere C; Monnet J; Racault AS; Wynne C
    Expert Rev Clin Immunol; 2022 May; 18(5):533-543. PubMed ID: 35354411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and tolerability of prefilled syringe and auto-injector presentations of MSB11456: results of a randomized, single-dose study in healthy adults.
    Tomaszewska-Kiecana M; Dryja A; Ullmann M; Petit-Frere C; Illes A; Dagres C; Monnet J
    Expert Rev Clin Immunol; 2023 Apr; 19(4):447-455. PubMed ID: 36789991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study.
    Yu KS; Kim B; Shin D; Park MK; Hwang JG; Kim MG; Chung H; Ghim J; Chung JY; Smolen JS; Burmester GR; Kim S; Bae Y; Jeon D; Yoo J; Yang G; Bae J; Keystone E
    Expert Opin Investig Drugs; 2023 May; 32(5):429-439. PubMed ID: 37231670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy and safety of a proposed biosimilar MSB11456 with tocilizumab reference product in subjects with moderate-to-severe rheumatoid arthritis: results of a randomised double-blind study.
    Zubrzycka-Sienkiewicz A; Klama K; Ullmann M; Petit-Frere C; Baker P; Monnet J; Illes A
    RMD Open; 2024 Feb; 10(1):. PubMed ID: 38316489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study.
    Yu KS; Ryu H; Shin D; Park M; Hwang J; Moon SJ; Kim MG; Keystone E; Smolen JS; Kim S; Bae Y; Jeon D; Jang J; Yang G; Bae J; Lee J; Burmester GR
    Expert Opin Biol Ther; 2024 Jul; 24(7):681-689. PubMed ID: 38905143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta
    Moosavi S; Borema T; Ewesuedo R; Harris S; Levy J; May TB; Summers M; Thomas JS; Zhang J; Yao HM
    Adv Ther; 2020 Jul; 37(7):3370-3391. PubMed ID: 32524499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial.
    Lickliter J; Kanceva R; Vincent E; Schueler A; Harrison-Moench E; Yue CS; Stahl M; Ullmann M; Ghori V; Griffin P
    Clin Ther; 2020 Aug; 42(8):1508-1518.e1. PubMed ID: 32660769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects.
    Yang J; Lin L; Long Q; Zhang Q; Sun G; Zhou L; Wang Q; Zhu J; Li F; Hu W
    BioDrugs; 2022 May; 36(3):393-409. PubMed ID: 35594017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study comparing the pharmacokinetics and safety of HS628 (tocilizumab biosimilar) and reference tocilizumab in healthy male subjects.
    Qian H; Cheng J; Gui Y; Wang W; Liang L; Zhu H; Wu Q; Ou M; Chen Q; Yu C; Jia J
    Clin Transl Sci; 2023 Sep; 16(9):1704-1712. PubMed ID: 37403258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, parallel-group, single-dose comparative pharmacokinetic study of DRL_TZ, a candidate biosimilar of trastuzumab, with Herceptin
    Lickliter JD; Dadhania RN; Trivedi RK; Naveen Kumar SR; Reddy PK
    Indian J Med Res; 2021 Mar; 154(3):509-519. PubMed ID: 35142643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial.
    Leng X; Leszczyński P; Jeka S; Liu SY; Liu H; Miakisz M; Gu J; Kilasonia L; Stanislavchuk M; Yang X; Zhou Y; Dong Q; Rezk M; Mitroiu M; Addison J; Zeng X
    Lancet Rheumatol; 2024 Jan; 6(1):e40-e50. PubMed ID: 38258678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin
    Li H; Zhao X; Xie J; Zhu X; Su Y; He C; Ding J; Zhu M; Xu Y; Wang Y; Shan R; Liu B; Ding Y; Liu Y; Zhou H; Xie Y
    BMC Pharmacol Toxicol; 2023 May; 24(1):36. PubMed ID: 37245022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin
    Wu X; Wynne C; Xu C; Gan Y; Wang C; Thomas BE; Yu JC; Li S; Zhang L
    BioDrugs; 2019 Jun; 33(3):335-342. PubMed ID: 31016568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers.
    Shin D; Lee YJ; Choi J; Lee D; Park M; Petkova M
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):567-575. PubMed ID: 32949267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women.
    Fenwick S; Vekariya V; Patel R; Hajela P; Modi K; Kale P; Nath A
    Osteoporos Int; 2023 Jan; 34(1):179-188. PubMed ID: 36287230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab.
    Esteva FJ; Stebbing J; Wood-Horrall RN; Winkle PJ; Lee SY; Lee SJ
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):505-514. PubMed ID: 29330636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects.
    Liu YN; Huang J; Guo C; Yang S; Ye L; Wu ST; Zhang XF; Yang XY; Han CC; Pei Q; Huang L; He QN; Yang GP
    Cancer Chemother Pharmacol; 2020 Mar; 85(3):555-562. PubMed ID: 31907645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST).
    Wynne C; Schwabe C; Lemech C; Stroissnig H; Dias R; Sobierska J; Guenzi E; Otto H; Sattar A; Kay R; Haliduola HN; Berti F
    Expert Opin Investig Drugs; 2022 Sep; 31(9):965-976. PubMed ID: 35107050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers.
    Sinn A; García-Alvarado F; Gonzalez V; Huerga C; Bullo F
    Br J Clin Pharmacol; 2022 Mar; 88(3):1063-1073. PubMed ID: 34374114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.